Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives
International Ophthalmology · 2024
DOI: 10.1007/s10792-024-03000-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Ophthalmology, 2024. Verfasst von Pradip Nirbhavane und 3 weiteren Autor:innen. Beteiligte Einrichtung: Amity University Haryana, Gurugram, 122413, India. pnirbhavane@ggn.amity.edu. Hauptthemen laut MEDLINE: Uveitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Intraocular inflammation, commonly referred to as uveitis, is a prevalent ocular disease. The categorization of uveitis may be based on the prevailing anatomical site, which includes anterior, intermediate, and posterior uveitis. There exists a significant body of evidence indicating that T cells play a pivotal role in the pathogenesis of autoimmune uveitis. In addition to the presence of T cells, an elevation in levels of inflammatory cytokines and a reduction in regulatory cytokines were also noted. The primary pharmacological interventions for uveitis comprise of corticosteroids, methotrexate, anti-vascular endothelial growth factor (VEGF) agents, anti-tumor necrosis factor-alpha (TNF-α) antibodies, and sirolimus. These medications offer prompt alleviation for inflammation. Nevertheless, prolonged administration of corticosteroids invariably leads to unfavorable adverse reactions. The traditional topical corticosteroids exhibit certain limitations, including inadequate transcorneal permeation and low corneal retention, leading to reduced ocular bioavailability. Consequently, there is a growing inclination towards the creation of innovative steroid drug delivery systems with the aim of reducing the potential for adverse effects, while simultaneously enhancing the drug's corneal permeation and retention. CONCLUSION: This review is an attempt to compile all the research work done so far in this field and provides a brief overview of the global efforts to develop innovative nanocarrier-based systems for corticosteroids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity University Haryana, Gurugram, 122413, India. pnirbhavane@ggn.amity.edu.
- University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
- Amity University, Gwalior, Madhya Pradesh, 474005, India.
Zitieren
APA
Nirbhavane, P., Sharma, G., Sharma, R., & Katare, O. P. (2024). Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives. International Ophthalmology. https://doi.org/10.1007/s10792-024-03000-4
Vancouver
Nirbhavane P, Sharma G, Sharma R, Katare OP. Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives. International Ophthalmology. 2024. doi:10.1007/s10792-024-03000-4
BibTeX
@article{Nirbhavane2024,
author = {Nirbhavane, Pradip and Sharma, Gajanand and Sharma, Rajeev and Katare, O P},
title = {Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives},
journal = {International Ophthalmology},
year = {2024},
doi = {10.1007/s10792-024-03000-4}
}
EUVIMED